The developed world is familiar with the global threats of viral infections that incite fear in both rich populations and poor. The pandemics of SARS, and avian and swine influenza have cost the global economy an estimated US$200 billion. These threats emerge frequently and unpredictably from human contact with animals. Rapid response is required of governments, UN agencies, regulatory authorities and the pharmaceutical industry for coordination, surveillance and vaccine production.
But the poorest people — those who live on less than US$2 per day — are often not considered important when a pandemic threat emerges. They do not contribute significantly to the global economy, and their countries’ health systems function on a tiny fraction of what advanced economies devote to their populations’ health.
Conversely, the developed countries’ view of the diseases of the developing world is that only three are important: AIDS, tuberculosis and malaria. This stems from the power of advocacy constituencies and the recognition that these diseases might threaten the developed world. As a result, these diseases receive a disproportionate amount of funding for research and control, while other infections kill, blind, deform and disable many more — the “bottom billion” — who have little access to healthcare.
These infections are known as the Neglected Tropical Diseases (NTDs). They are unfamiliar to the developed world, and their names are often difficult to pronounce: filariasis (elephantiasis), onchocerciasis (river blindness), schistosomiasis (bilharzia) and others, particularly intestinal worms.
These are not familiar diseases to people lucky enough to live in the world’s richest countries, but they are household names to hundreds of millions of poor people, who are often infected with more than one of them. They are long-lasting conditions, often contracted at an early age, and both the illnesses and their symptoms are progressive.
Indeed, whereas the misery that worm diseases cause is extensive and the burden excessive — as much as tuberculosis or malaria — they do not kill immediately. Instead, they gradually erode children’s development prospects.
And symptoms accumulate: Sight is gradually lost, genital lesions appear around puberty (sometimes increasing the risk of HIV) and skin condition declines as millions of microscopic worms become intolerably itchy. Blood loss, causing anemia, is the result of thousands of worms chewing at the wall of the gut.
Other diseases, such as sleeping sickness, transmitted by tsetse flies, are fatal if untreated, as is leishmaniasis, if the parasites that cause it — transmitted by tiny sandflies — invade the liver and spleen. Again, the misery caused by these infections exceeds the burden of tuberculosis or malaria.
The good news is that NTDs can be treated, as quality drugs — donated by the major pharmaceutical companies — are made available.
These drug donations for river blindness, trachoma (another blinding disease), leprosy, elephantiasis, worms and bilharzia, as well as for sleeping sickness, give hope to millions.
Moreover, the cost of the annual treatment recommended by the WHO is often less than US$0.50, and much less in Asia, with delivery carried out by communities or through schools. The increase in treatment has been spectacular — more than 500 million people in 51 countries treated for elephantiasis in 2007, and 60 million in 19 countries have been treated for river blindness. Guinea disease is now endemic in only four countries, and leprosy is a problem in only six.
These are impressive figures, and the expense is trivial compared to the anti-retroviral drugs needed to treat AIDS, which cost more than US$200 annually and must be taken every day, not every year. Given that roughly 1 billion people are infected with NTDs, compared to 40 million with HIV, and that the drugs targeting them are donated and actually prevent disease and stop transmission, treating NTDs is a major opportunity to lift populations out of poverty.
The main challenge is to convince policymakers that there is more to reducing poverty than focusing on just three diseases. In fact, NTDs are “low-hanging fruit.” If the international community is serious about alleviating poverty and achieving development goals, tackling the diseases so directly associated with economic misery should be a fundamental objective.
We can easily meet that objective, because we have drugs that are effective, free (or very cheap), that have low delivery costs, and that provide add-on benefits. Now is the time to rethink our public-health investments and messaging, and evaluate whether we are getting the best value for our donor dollars, or whether we should do much more to tackle diseases that we have so far largely ignored.
David Molyneux is a professor emeritus at the Liverpool School of Tropical Medicine.
Copyright: Project Syndicate
Congressman Mike Gallagher (R-WI) and Congressman Raja Krishnamoorthi (D-IL) led a bipartisan delegation to Taiwan in late February. During their various meetings with Taiwan’s leaders, this delegation never missed an opportunity to emphasize the strength of their cross-party consensus on issues relating to Taiwan and China. Gallagher and Krishnamoorthi are leaders of the House Select Committee on the Chinese Communist Party. Their instruction upon taking the reins of the committee was to preserve China issues as a last bastion of bipartisanship in an otherwise deeply divided Washington. They have largely upheld their pledge. But in doing so, they have performed the
It is well known that Chinese President Xi Jinping’s (習近平) ambition is to rejuvenate the Chinese nation by unification of Taiwan, either peacefully or by force. The peaceful option has virtually gone out of the window with the last presidential elections in Taiwan. Taiwanese, especially the youth, are resolved not to be part of China. With time, this resolve has grown politically stronger. It leaves China with reunification by force as the default option. Everyone tells me how and when mighty China would invade and overpower tiny Taiwan. However, I have rarely been told that Taiwan could be defended to
It should have been Maestro’s night. It is hard to envision a film more Oscar-friendly than Bradley Cooper’s exploration of the life and loves of famed conductor and composer Leonard Bernstein. It was a prestige biopic, a longtime route to acting trophies and more (see Darkest Hour, Lincoln, and Milk). The film was a music biopic, a subgenre with an even richer history of award-winning films such as Ray, Walk the Line and Bohemian Rhapsody. What is more, it was the passion project of cowriter, producer, director and actor Bradley Cooper. That is the kind of multitasking -for-his-art overachievement that Oscar
Chinese villages are being built in the disputed zone between Bhutan and China. Last month, Chinese settlers, holding photographs of Chinese President Xi Jinping (習近平), moved into their new homes on land that was not Xi’s to give. These residents are part of the Chinese government’s resettlement program, relocating Tibetan families into the territory China claims. China shares land borders with 15 countries and sea borders with eight, and is involved in many disputes. Land disputes include the ones with Bhutan (Doklam plateau), India (Arunachal Pradesh, Aksai Chin) and Nepal (near Dolakha and Solukhumbu districts). Maritime disputes in the South China